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1. Introduction  
The incidence of melanoma continues to rise, in particular among adult males residing in 
the U.S. (Jemal, Siegel et al. 2010). Although this disease is treatable in its early stages, 
diagnosis of or progression to an advanced, metastatic disease stage drastically reduces the 
prognosis, with few patients surviving 5 years. It is especially disturbing that there is a lack 
of FDA-approved therapeutics that can adequately treat the disease and very low 
percentages (5-15%) of patients who will respond to these traditional chemotherapeutics 
(Thompson, Morton et al. 2004). Even among responders, the response to therapy is usually 
unsustainable over the long-term, with approximately 10.8% of patients achieving long-term 
survival (Kim, Lee et al. 2010). Dacarbazine or DTIC is considered the most appropriate 
cytotoxic chemotherapy, but response rates are poor. Many other single-agents have been 
tried with response rates ≤18%, these include temozolomide, lomustine, carmustine, 
cisplatin, carboplatin, vincristine, vinblastine, vindesine, paclitaxel, docetaxel, gemcitabine 
and topotecan. (Thompson, Morton et al. 2004) 
Without patient selection to decipher who belongs to the small portion of responders, the more 
common approach to therapy is to enroll patients into a clinical trial. Recent trials examining 
more targeted and selective agents like PLX4032 (Flaherty, Puzanov et al. 2010) and 
ipilimumab (Hodi, O'Day et al. 2010) have further reinforced this clinical ideology due to the 
successes observed among some patients. Although the development of chemoresistance is an 
impediment to achieving cure using these novel agents, they represent the current ideal and a 
hopeful future for promising targeted therapeutics. Thus, more specific drugs are desirable to 
increase the options for therapy and improve overall outcomes. 
A recently discovered and highly “druggable” method to target melanoma cells is through 
inhibition of a G protein-coupled receptor (GPCR) that is responsible for viability among 
melanomas that predominantly express it (Altman, Gopal et al. 2010). This GPCR is called 
the Lysophosphatidic Acid (LPA) receptor 3 or the LPA3 receptor (Bandoh, Aoki et al. 1999) 
and is found along the cell surface of specific types of melanomas. In addition, the high-
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affinity ligand that binds to this GPCR is lysophosphatidic acid (Aoki, Bandoh et al. 2000). 
Interestingly, the lysophospholipase D that is responsible for the vast majority of the 
production of LPA from lysophosphatidylcholine is also expressed extracellularly and is a 
major target in melanoma (Altman et al. 2010; Liu, Murph et al. 2009). This enzyme, autotaxin 
(ATX), was first isolated from the conditioned medium of melanoma cells and was thought to 
be responsible for melanoma cell motility (Stracke, Krutzsch et al. 1992). Recent studies have 
shown that targeting either the LPA3 receptor or ATX effectively reduces melanoma cell 
viability (Altman et al. 2010). Furthermore, research devoted to producing inhibitors and 
antagonists targeting the ATX-LPA receptor axis has yielded a large variety of compounds 
(Albers, Dong et al. 2010; Altman et al. 2010; Baker, Fujiwara et al. 2006; Block, Duff et al. 2010; 
Hoeglund, Bostic et al. 2010; Hoeglund, Howard et al. 2010; North, Howard et al. 2010; Xu, 
Yang et al. 2009), suggesting the critical role of this pathway in cancer. 
Herein we tested the in vitro capability of another antagonist of the LPA3 receptor and the 
lysophospholipase D activity of autotaxin, BrP-LPA, among the MeWo melanoma cell line. 
This compound inhibits the growth of in vivo lung carcinoma and angiogenesis (Xu and 
Prestwich 2010), but was untested in melanoma, a disease in dire need of additional 
therapeutics. We compared the BrP-LPA anti diastereoisomer to the BrP-LPA 
diastereomeric mixture and observed a slight enhancement of activity against MeWo cells 
using the mixture. Surprisingly, this effect was reduced or absent in the presence of a 24-
hour pretreatment with dacarbazine, a traditional alkylating chemotherapeutic agent, 
suggesting that single-agent therapy is superior. We have observed an in vivo effect on 
reducing the number of metastatic melanoma lesions in the lungs of mice treated with BrP-
LPA, in comparison to control (data not shown). It is unclear whether our in vitro results 
would extend to in vivo treatment, but if so, then the implications of this study would 
require naïve patients for clinical trials, an extremely difficult group to have available. 
2. Materials and methods 
MeWo fibroblast malignant melanoma cells were acquired from ATCC (Manassas, VA) and 
maintained in Cellgro RPMI (Mediatech, Inc., Manassas, VA) supplemented with 5% fetal 
bovine serum (Sigma-Aldrich, St Louis, MO). BrP-LPA compounds, the anti diastereoisomer 
and diastereomeric mixture, were synthesized as previously described (Zhang, Xu et al. 
2009) and reconstituted in water prior to use. The alkylating agents temozolomide (TMZ) 
and dacarbazine (DTIC) were purchased from Sigma-Aldrich. 
2.1 Cell viability 
MeWo cells were examined for viability by seeding cells (10 x 103) in quadruplicates in 96-
well plates. Cells were allowed to attach to the 96-well plate overnight in 5% FBS containing 
medium prior to the indicated drug treatment and concentration for 36 hours. CellTiter™ 
Blue reagent (Promega, Madison, WI) was added to plates and cells were incubated at 37°C 
to assess viability as previously described (Altman et al. 2010; Hasegawa, Murph et al. 2008).  
2.2 High-throughput proliferation imaging 
To examine the effects of cell proliferation in the presence of monotherapy, 10 x 103 MeWo 
cells were plated in quadruplicates in 96-well plates. After overnight incubation at 37 °C, the 
indicated drug and concentration was administered to the cells and the plates were 
incubated for another 30-40 h. After this incubation the cells were fixed in 2% formaldehyde 
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and stained using the Multiparameter Cytotoxicity II kit (ThermoScientific, Pittsburgh, PA), 
according to the directions provided by the manufacturer. To obtain the results, the plates 
were then quantified and visualized using the ArrayScan®VTI HCS Reader (Thermo 
Scientific). For combination drug treatments, approximately 2,500 MeWo cells were plated 
in 96-wells and allowed to attach overnight. DTIC was added at the indicated concentration 
for 24 h followed by the addition of BrP-LPA for 24 h. The cells were fixed and stained using 
the Multiparameter Cytotoxicity III kit and then following the directions given in the 
manufacturer’s protocol (Thermo Scientific). 
2.3 Statistical analysis 
Statistical differences in experimental data was determined using analysis of variance 
(ANOVA) followed by either Tukey’s test or Bonferroni’s multiple comparison test between 
groups. Alternatively, single comparisons were calculated using the student’s t-test. 
GraphPad Prism (La Jolla, CA) was used to facilitate the statistical tests performed. *p < 0.05 
**p < 0.01 and ***p < 0.001 indicate the levels of significance.  
3. Results  
Figure 1 shows the chemical structures of the two BrP-LPA compounds used. Figure 1A 
shows the relative anti-configuration of the bromo substituent relative to the natural 
configuration of the sn-2 hydroxyl of LPA, while Figure 1B shows the diastereomeric 
mixture of syn- and anti-bromo substituents.  
 
 
The structures of the anti diastereoisomer of 16:0 BrP-LPA (A) and its diastereomeric mixture (B) are 
depicted. 
Fig. 1. Chemical structures.  
We compared these two preparations in a viability curve, which accounts for both 
proliferation and metabolism, using MeWo melanoma cells. In the viability assay, we 
measured IC50 values of 17.68 μM and 16.76 μM for the anti diastereoisomer and the 
diastereomeric mixture, respectively (Figure 2A and 2B). Upon further analysis, the mixture 
(Figure 1B) consistently demonstrated increased ability to reduce cell viability over anti-BrP-
LPA (Figure 1A), especially at the highest concentration (100 μM) tested (Figure 2C).  
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Cell viability assays using MeWo cells treated with increasing doses of the BrP-LPA anti 
diastereoisomer (A) or diastereomeric mixture (B) are log transformed and depicted here. (C) A bar 
graph showing the range of concentrations used in MeWo cells compares the reduction in viability 
achieved between the two BrP-LPA reagents. (D) Comparison between the two BrP-LPA reagents and 
other single-agent treatment with dacarbazine (DTIC) or temozolomide (TMZ) demonstrates potency of 
the BrP-LPA diastereomeric mixture (100 μM and 10μM) surpasses that achieved by either DTIC or 
TMZ at higher doses (1000 μM and 100 μM). Similar results are also seen with the BrP-LPA anti 
diastereoisomer. Brackets at the top indicate which single-agent was used. *p<0.05, **p<0.01 or 
***p<0.001, compared to DMSO control-treated MeWo cells. 
Fig. 2. Single-agent treatment with BrP-LPA compounds reduces cell viability at lower doses 
than dacarbazine or temozolomide.  
We next sought to evaluate how these agents measured up against chemotherapy. In 
comparison to single-agent BrP-LPA treatment versus traditional alkylating chemotherapy, 
the BrP-LPA compounds showed more activity in reducing cell viability, even at lower 
concentrations than the chemotherapy (Figure 2D). For example, 100 μM or 10 μM of BrP-
LPA (Figure 1B) was more effective at reducing viability than 1000 μM of dacarbazine 
(DTIC) or temozolomide (TMZ). At 100 μM of DTIC or TMZ, the modest reduction in 
viability was not statistically different than diluent control (DMSO). Similar observations 
occurred with the anti-BrP-LPA (Figure 1A)  as well. 
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(A) MeWo cells were either untreated, or treated with 12.5 μM BrP-LPA reagents for 36 hours, fixed, 
processed and stained for immunofluorescence visualization. (B) The average number of cells per field 
was calculated by automated measurements of quadruplicate well samples using the ArrayScan®VTI 
HCS Reader, as a measurement of the cell proliferation achieved in the presence of either 0, 1.6, 3.1, 6.25 
or 12.5 μM of the BrP-LPA diastereomeric mixture or the anti diastereoisomer. (C) Using a nuclear 
permeability dye, the increase in fluorescence intensity was automatically measured by the 
ArrayScan®VTI HCS Reader using quadruplicate samples. *p<0.05, **p<0.01 or ***p<0.001, compared to 
0 μM or untreated MeWo cells. 
Fig. 3. MeWo cell proliferation is reduced after treatment with BrP-LPA reagents. 
Since the assay measuring cell viability accounts for both the proliferation and metabolism 
of cells, we sought to discriminate these two features by looking solely at the rate of in vitro 
growth or proliferation in the presence of BrP-LPA. After treating MeWo cells for 36 hours 
in the presence of increasing concentration of drug (Figure 3A), we assessed the number of 
surviving cells using high-throughput imaging for quantification. Strikingly, even the 
lowest concentration of the mixture BrP-LPA (Figure 1B) (1.6 μM) showed a significant 
decrease in the number of cells captured per field compared with untreated cells (Figure 3B). 
At the highest dose (12.5 μM), an obvious shift in cell number was visually observed (Figure 
3A) and was also quantified as statistically significant versus untreated cells (Figure 3B). 
Although a reduction in cell number was detected among cells treated with the anti-BrP-
LPA (1A), the reductions were significant only at 6.25 μM and 12.5 μM. Dying cells display 
many morphological changes, including nuclear condensation and permeabilization that 
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can be visualized by an intense increase in the fluorescence intensity of cell nuclei. We 
quantified nuclear permeability and detected an initial reduction (1.6 μM and 3.1μM), 
followed by a significant increase at higher concentrations (6.25 μM and 12.5 μM) in MeWo 
cells treated with the BrP-LPA mixture (Figure 1B) (Figure 3C). Although the results from 
the anti-BrP-LPA (Figure 1A) were not significant, there did appear to be an increasing 
trend at higher concentrations (6.25 μM and 12.5 μM).  
Due to the favorable results we observed thus far in our analysis, we hypothesized that the 
combinatorial treatment of BrP-LPA compounds with the alkylating agent DTIC would 
have superior activity to reduce MeWo cell viability than single-agent BrP-LPA treatment. 
In contrast, we observed an increase in the number of remaining MeWo cells after 24 hours 
treatment with DTIC, followed by 24 hours of the BrP-LPA compounds (Figure 4A). We 
quantified the changes in the loss of cells and determined monotherapy of BrP-LPA to be 
superior in comparison with combinatorial treatment (Figure 3B and 3C).  
Only when DTIC was reduced to 50 μM did the significance return, suggesting that a low 
enough concentration eliminated the combined inhibition. Similarly, we detected plasma 
membrane permeability only among DTIC 1000 μM and single-agent anti or mix (10 μM). 
There was a slight increase in the permeability at 50 μM DTIC and 10 μM of anti or mix, 
further supporting the observation that the low dose of DTIC eliminates the combined 
inhibition. Since the drugs were administered 24 hours apart, we hypothesize this is due to 
the molecular and cellular response to the compound, within the context of proliferation or 
an effect related to chemoresistance. This could suggest that the BrP-LPA compounds would 
require chemonaïve patients to achieve therapeutic efficacy, and this group would be 
incredibly difficult to find. 
4. Discussion 
Our data suggests, at least in an in vitro comparison, that single-agent or monotherapy 
using the anti-BrP-LPA (Figure 1A) or the mixed diastereomers BrP-LPA (Figure 1B) is 
superior at reducing the viability and proliferation of MeWo primary cutaneous melanoma 
cells than dacarbazine or temozolomide. Although we hypothesized that the mechanism of 
action for these two different agents would create a synergistic response as others have seen 
using combinations of dacarbazine with unrelated agents (Jin, Gong et al. 2011), in fact that 
is not what was observed. While unexpected, our results are similar to what others have also 
observed using BrP-LPA. Using an in vivo breast cancer model, Zhang et al. reported that 
the mixed diastereomers BrP-LPA (Figure 1B) alone (10 mg/kg) was superior at reducing 
tumor burden, compared with taxol alone (10 mg/kg) or taxol followed by BrP-LPA (Zhang 
et al. 2009). This corroborates our observations and further predicts that similar effects are 
likely to occur in an in vivo model of melanoma. Indeed, we have tested single-agent BrP-
LPA against metastatic melanoma in vivo and measured a significant reduction in the 
number of lesions in the lungs of animals (data not shown).  
The concern over reduced response with combination treatment of a novel agent together 
with dacarbazine is a major concern since most chemotherapy is now given in combination, 
even in clinical trials (Chu and DeVita 2008). In our study, we staged the drugs 24 hours 
apart, yet we still observed a reduction in overall efficacy. Our results are also in agreement 
with other publications suggesting that dacarbazine selects for a more aggressive phenotype 
 
www.intechopen.com
A Bromophosphonate Analogue of Lysophosphatidic Acid  
Surpasses Dacarbazine in Reducing Cell Proliferation and Viability of MeWo Melanoma Cells 
 
77 
 
 
(A) Fluorescent images of MeWo cells treated with the indicated reagents for 24 or 48 h. The 
combination treatments were staged so that the dacarbazine (DTIC) was added for 24 h prior to the 
addition of BrP-LPA for an additional 24 h, for a total of 48 h of dacarbazine. The single-agent 
treatments were for 24 h. (B and C) Cell loss was calculated by measuring the average number of cells 
lost per field from quadruplicate samples and at least 4 images taken per sample for N=16. The BrP-
LPA diastereomeric mixture was used in ‘B’ and the anti diastereoisomer was used in ‘C’. (D) Plasma 
membrane permeability was calculated after staining the MeWo cells with a fluorescent dye capable of 
penetrating the membrane when small pores or holes provide access for the dye to enter the cell. An 
increase in the membrane permeability was achieved in the single-agent conditions or when DTIC was 
very low (50 μM), although statistical significance (***p<0.001) was calculated for only the BrP-LPA 
diastereomeric mixture (10 μM) in comparison with DMSO (1 μM) control using the student’s t-test. 
Fig. 4. Combination treatment of BrP-LPA reagents with dacarbazine inhibits the reduction 
in cell loss and proliferation achieved using single-agents. 
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of melanoma, which may occur through the upregulation of ERK signaling pathways, 
cytokine release or increased vascular endothelial growth factor (Lev, Onn et al. 2004). In 
this study  we also observed what others have reported in that melanomas are notoriously 
resistant to therapeutic intervention. Indeed, we also found this to be true after only 24 
hours of exposure to dacarbazine, which was unexpected given the short timecourse. 
Herein we showed a reduction in cell viability using BrP-LPA compounds over the 
traditional chemotherapy alkylating agents, even when using BrP-LPA at lower 
concentrations. This highlights two important points concerning current therapeutics of 
melanoma. First, the traditional alkylating agents lack sufficient potency against this type of 
tumor, even when drug delivery is removed from the equation through the use of an in 
vitro tissue culture model. Second, single-agent BrP-LPA could be far better in generating a 
reduction in tumor burden and clinical usage than the alkylating agents.  
In comparison with other agents that we have tested, the BrP-LPA compounds can generate 
a more robust effect against certain types of melanoma than thio-ccPA 18:1, which requires a 
higher dosage in vitro (Altman et al. 2010). Furthermore, in a direct comparison between 
anti-BrP-LPA (Figure 1A) and the mixed diastereomers BrP-LPA (Figure 1B), we repeatedly 
observed an enhanced effect of the mixture. Thus far, in vivo studies have not detected any 
known cytotoxicity of this compound (data not shown), which further indicates its utility. 
Taken together, this is suggestive of the clinical potential of BrP-LPA in advanced 
melanoma. 
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